Bevacizumab
Monoclonal antibody targets VEGFA
Regulatory milestones approvals, filings & regulatory actions · 19 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Ipique | — | 2022-04-29 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | MVASI | — | 2019-06-24 – 2021-11-15 | fda.gov ↗ |
| Label expansions (14) | US (FDA) | AVASTIN | — | 2005-09-29 – 2020-05-29 | fda.gov ↗ |
| Approved | EU (EMA) | Avastin | — | 2005-01-12 | europa.eu ↗ |
| Approved | US (FDA) | AVASTIN | — | 2004-02-26 | fda.gov ↗ |
Trials 2,041 · started per year
Press releases naming this drug 218 releases
Evidence & citations 57 cited values
Every value below carries the sentence it was read from. 2,787 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bevacizumab | “This study is to prove that the handling (also referred to as pharmacokinetics) of the following drugs PF-06439535, Avastin® (bevacizumab) that is licensed for use in the...” NCT02031991 ↗2659“Investigator's choice of standard first-line systemic therapy for initially unresectable colorectal cancer, including chemotherapy (e.g., FOLFOX, FOLFIRI, CAPOX) with or...” NCT07509398 ↗ “EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered...” NCT04116658 ↗ “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗ “The vascular endothelial growth factor pathway is biologically important in pancreatic cancer, and docetaxel has modest antitumor activity. We evaluated the role of the...” PMID 20458210 ↗ Feb 2011 “Fudan CUP-002 study (ClinicalTrials.gov identifier: NCT04848597), an investigator-initiated prospective trial, was designed to evaluate the efficacy and safety of an anti-PD-1...” PMID 42103741 ↗ May 2026 “Treatment-naïve NSCLC patients with brain metastasis harboring EGFR-activating mutations were treated with osimertinib 80 mg oral daily and bevacizumab 15 mg/kg intravenously...” PMID 37016906 ↗ Apr 2023 “Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗ “Another recent trial in patients with advanced HCC demonstrated improved survival with the combination of Atezolizumab, an immune checkpoint inhibitor (ICI), and Bevacizumab,...” NCT05137899 ↗ “Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Oxaliplatin 130mg/m2+Capecitabine 1250mg/m2 for 6-8cycles, Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Capecitabine 1250mg/m2 as maintenance...” NCT06973343 ↗ “Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of...” NCT04954794 ↗ |
| Known as | Altuzan | “Bevacizumab (Altuzan) was injected subconjunctival space of the patients.” NCT02796183 ↗ |
| Known as | Anda | “Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).” NCT05364489 ↗ |
| Known as | Avastin | “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗282“The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two...” NCT03919448 ↗ “Terence M. Davidson, MD is conducting a research study to find out more about the topical application of Avastin (proper chemical name is bevacizumab) in the treatment of...” NCT01397695 ↗ “Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous...” PMID 34184418 ↗ Jun 2021 “In clinic, recent studies showed a significant benefit of bevacizumab (Avastin®) in the treatment of primary brain tumors, as shown by Vredenburgh et al. for patients with...” NCT01332929 ↗ “The FDA has also approved the use of a drug called bevacizumab (or Avastin) in combination with FOLFIRI, and this is considered one of the standards of care for all patients...” NCT01183494 ↗ “The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal...” NCT00461773 ↗ “The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with...” NCT00308607 ↗ “Bevacizumab (Avastin®): 5 mg/kg IV infusion in 100 mL of 0.9% saline over 90 minutes for the first infusion, then 60 minutes for the second infusion if tolerated, and 30...” NCT00467142 ↗ “A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the...” NCT02214628 ↗ “Preoperative administration of bevacizumab (Avastin; Genentech, Inc, South San Francisco, California, USA), a full-length recombinant humanized monoclonal antibody targeting...” NCT02590094 ↗ |
| Known as | Avastin (bevacizumab) | “Avastin® (bevacizumab)” NCT01295112 ↗10“Avastin® (bevacizumab)” NCT00365365 ↗ “Avastin (bevacizumab)” NCT00979017 ↗ “Avastin (bevacizumab)” NCT01434147 ↗ “Avastin (bevacizumab)” NCT01186406 ↗ “Avastin: bevacizumab.” NCT00462423 ↗ “Avastin (bevacizumab)” NCT01531595 ↗ “Avastin - Bevacizumab” NCT00612339 ↗ “Avastin(BEVACIZUMAB)” NCT02594423 ↗ “Avastin (Bevacizumab” NCT00845884 ↗ “Avastin, bevacizumab” NCT01231633 ↗ |
| Known as | AvastinR | “Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28:...” NCT00628810 ↗ |
| Known as | Avastinâ | “Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated...” NCT00177307 ↗ |
| Known as | AvastinÒ | “Bevacizumab (AvastinÒ) will be given intravenously at 10 mg/kg every other week.” NCT00350753 ↗ |
| Known as | Avatstin | “Bevicizumab (Avatstin) is a humanized monoclonal antibody to VEGF.” NCT00586443 ↗ |
| Known as | BE1040V | “Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer” PMID 32334845 ↗ Apr 2020 |
| Known as | Bev | “Based on the synergistic potential of radiotherapy and angiogenesis inhibitors, we initiated this phase II study to assess the efficacy and safety of combining bevacizumab...” PMID 41235462 ↗ Nov 202524“Participants in the atezolizumab plus bevacizumab (Atezo + Bev) arm will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31)...” NCT07018947 ↗ “The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2...” PMID 28459938 ↗ Aug 2017 “Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with...” NCT06739252 ↗ “This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in...” NCT06329570 ↗ “Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting VEGF (vascular endothelial growth factor) that is currently used in recurrent GBM, particularly in...” NCT02898012 ↗ “This randomized phase II-III trial sought to evaluate the efficacy and safety of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung...” PMID 25688059 ↗ Feb 2015 “Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC).” PMID 32201506 ↗ Mar 2020 “TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.” NCT07736937 ↗ “Atezolizumab (Atez) combined with bevacizumab (Bev) is the recommended first-line treatment for unresectable hepatocellular carcinoma (HCC).” PMID 40891895 ↗ Sep 2025 “Bevacizumab (Bev), an anti-tumor angiogenesis monoclonal antibody, combined with chemotherapy has been shown effective in advanced GC.” NCT02048540 ↗ |
| Known as | Bevacizumab (Avastin) | “bevacizumab ( Avastin )” NCT00681603 ↗21“Bevacizumab (Avastin).” NCT02072720 ↗ “Bevacizumab (Avastin™)” NCT00604461 ↗ “Bevacizumab (Avastin )” NCT01195298 ↗ “bevacizumab (Avastin®)” NCT01067053 ↗ “Bevacizumab (Avastin)” NCT03585556 ↗ “Bevacizumab (Avastin)” NCT02348359 ↗ “Bevacizumab = Avastin” NCT00359164 ↗ “Bevacizumab (Avastin)” NCT00939991 ↗ “Bevacizumab (Avastin)” NCT00161291 ↗ “Bevacizumab: Avastin®” NCT00585377 ↗ |
| Known as | Bevacizumab (Avastin;Genentech Inc,USA) | “Bevacizumab (Avastin;Genentech Inc,USA)” NCT02015351 ↗ |
| Known as | Bevacizumab (BP102) | “Bevacizumab (BP102)” NCT04395989 ↗1“Bevacizumab (BP102)” NCT05806060 ↗ |
| Known as | Bevacizumab (rhuMAb VEGF, Avastin), NSC 704865 | “Bevacizumab (rhuMAb VEGF, Avastin), NSC 704865” NCT00891527 ↗ |
| Known as | Bevacizumab Biosimilar CBT 124 | “Bevacizumab Biosimilar CBT 124” NCT00408694 ↗ |
| Known as | Bevacizumab Injection | “Bevacizumab injection (intravenous infusion, 7.5 mg/kg) administered every 21 days as one cycle, for a total of 2 cycles.” NCT07182708 ↗ |
| Known as | Bevacizumab Richmond | “Zutrab® (Bevacizumab Richmond)” NCT03919448 ↗ |
| Known as | Bevacizumab+ chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05555901 ↗ |
| Known as | Bevacizumab- also known as Avastin | “Bevacizumab- also known as Avastin” NCT00790010 ↗ |
| Known as | bevacizumab-800CW | “The purpose of this study was to determine the safety and feasibility of fluorescence molecular imaging using a commercially available system and intravenous injection of...” PMID 41344859 ↗ Jan 2026 |
| Known as | bevacizumab-awwb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185883 ↗ |
| Known as | Bevacizumab-EU | “reference bevacizumab (Avastin®) sourced from the European Union (bevacizumab-EU)” PMID 31768697 ↗ Nov 2019 |
| Known as | Bmab | “Bevacizumab (Bmab)” NCT02497157 ↗ |
| Known as | Brand name of Bevacizumab is Avastin | “Brand name of Bevacizumab is Avastin” NCT00548197 ↗ |
| Known as | BVC | “Association of Bevacizumab (BVC)+ Pazopanib (PZP)” NCT01202032 ↗ |
| Known as | BVZ | “Bevacizumab, BVZ (group A)” NCT06952452 ↗ |
| Known as | China-approved Avastin | “China-approved Bevacizumab® (Also Called China-approved Avastin)” NCT05378867 ↗ |
| Known as | Cizumab | “The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two...” NCT03919448 ↗ |
| Known as | CN-Avastin | “CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.” NCT03483649 ↗ |
| Known as | Dalutin | “Dalutin ® Bevacizumab 15mg/kg IV” NCT06590844 ↗ |
| Known as | Dayoutong injection | “bevacizumab (Dayoutong injection, 15 mg/kg)” NCT06995105 ↗ |
| Known as | EU-Avastin | “EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.” NCT03483649 ↗ |
| Known as | EU-bevacizumab | “BACKGROUND: MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab).” PMID 33914256 ↗ Apr 2021 |
| Known as | HLX04 | “AIM: To evaluate the efficacy and safety of HLX04-O, an investigational ophthalmic formulation of HLX04 (bevacizumab biosimilar) for intravitreal injection, as a treatment for...” PMID 36124180 ↗ Sep 2022 |
| Known as | HLX04 ( anti-VEGF antibody ) | “HLX04 ( anti-VEGF antibody )” NCT04465734 ↗ |
| Known as | HLX04-O | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740671 ↗ |
| Known as | IBI305 | “Bevacizumab Biosimilar IBI305” NCT05355155 ↗ |
| Known as | IVB | “The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a...” NCT00802126 ↗6“OBJECTIVE: To determine the efficacy of intravitreal bevacizumab (IVB) monotherapy versus a combination of IVB and suprachoroidal triamcinolone acetonide (SCTA) followed by...” PMID 42369925 ↗ Jun 2026 “comparing intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal triamcinolone acetonide (IVT) versus macular laser photocoagulation (MPC) as a...” PMID 22234244 ↗ Feb 2012 “To evaluate the effect of three intravitreal injections of bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractory...” PMID 17917738 ↗ Oct 2007 “PURPOSE: To compare the anatomical and functional outcomes of treatment with intravitreal bevacizumab (IVB) and topical timolol-dorzolamide versus IVB alone.” PMID 38376643 ↗ Feb 2024 “intravitreal bevacizumab (IVB) group with four monthly IVB injections” PMID 35594075 ↗ Jun 2022 “intravitreal bevacizumab (IVB)” PMID 31401683 ↗ Aug 2019 |
| Known as | Lumiere | “The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of...” NCT03668054 ↗ |
| Known as | MVASI | “MVASI® (bevacizumab-awwb) administered as an IV infusion.” NCT04185883 ↗ |
| Known as | Nelmastobart in combination with TAS-102 and Bevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07656038 ↗ |
| Known as | NSC # 704865 | “A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and...” NCT00079430 ↗4“The Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC # 704865, IND # 7,921) Administered in Times Sequential...” NCT00015951 ↗ “A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and...” NCT00436332 ↗ “A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma” NCT00052390 ↗ “A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas” NCT00445848 ↗ |
| Known as | Onbevzi | “bevacizumab (Onbevzi) at a dose of 15 mg/kg administered as a 30-minute intravenous infusion on Day 1 of each 21-day cycle” NCT07547592 ↗ |
| Known as | PRO-169 | “A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab).” NCT05217680 ↗ |
| Known as | R435 | “R435 (Bevacizumab) in Combination With Paclitaxel” NCT00467012 ↗ |
| Known as | rhuMAb VEGF | “The Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC # 704865, IND # 7,921) Administered in Times Sequential...” NCT00015951 ↗11“This is a pilot study in patients with previously untreated inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) to evaluate angiogenesis parameters after...” NCT00016549 ↗ “A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard...” NCT00109070 ↗ “A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and...” NCT00436332 ↗ “rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and...” NCT00066677 ↗ “A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas” NCT00445848 ↗ “The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.” NCT00061178 ↗ “A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer” NCT00025389 ↗ “Bevacizumab (aka Avastin or Rhu MAb VEGF)” NCT00047762 ↗ “rhuMAb VEGF (Bevacizumab)” NCT00109239 ↗ “rhuMAb VEGF” NCT01212822 ↗ |
| Known as | Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235930 ↗ |
| Known as | Stivant | “Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer” NCT03288987 ↗ |
| Known as | US-Avastin | “US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.” NCT03483649 ↗ |
| Known as | ZERIBEV | “Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody” NCT04344782 ↗ |
| Known as | Zirabev | “Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.” NCT05601973 ↗1“EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19” NCT04822818 ↗ |
| Known as | Zutrab | “The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two...” NCT03919448 ↗ |
| Action | Inhibit | “vascular endothelial growth factor is optimally inhibited” NCT00005061 ↗ |
| Modality | Monoclonal antibody | “Humanized Anti-VEGF Monoclonal Antibody” NCT00005061 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody VEGF (MOAB VEGF) IV over 1 hour” NCT00005061 ↗ |
| Target | VEGFA | “rhuMAb VEGF - recombinant humanized monoclonal antibody vascular endothelial growth factor (bevacizumab)” NCT00016549 ↗ |